technetium tc 99m hydroxymethylene diphosphonate and Bone Loss, Perimenopausal

technetium tc 99m hydroxymethylene diphosphonate has been researched along with Bone Loss, Perimenopausal in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Blake, GM; Fogelman, I; Moore, AE; Park-Holohan, SJ	1

Trials

1 trial(s) available for technetium tc 99m hydroxymethylene diphosphonate and Bone Loss, Perimenopausal

Article	Year
A direct in vivo measurement of 99mTc-methylene diphosphonate protein binding. Nuclear medicine communications, 2003, Volume: 24, Issue:7 Topics: Aged; Chromium Radioisotopes; Diagnostic Techniques, Radioisotope; Edetic Acid; Estrogen Replacement Therapy; Female; Glomerular Filtration Rate; Humans; Metabolic Clearance Rate; Middle Aged; Osteoporosis, Postmenopausal; Protein Binding; Radionuclide Imaging; Radiopharmaceuticals; Technetium Tc 99m Medronate	2003

Article

Year

A direct in vivo measurement of 99mTc-methylene diphosphonate protein binding.

Nuclear medicine communications, 2003, Volume: 24, Issue:7

Topics: Aged; Chromium Radioisotopes; Diagnostic Techniques, Radioisotope; Edetic Acid; Estrogen Replacement Therapy; Female; Glomerular Filtration Rate; Humans; Metabolic Clearance Rate; Middle Aged; Osteoporosis, Postmenopausal; Protein Binding; Radionuclide Imaging; Radiopharmaceuticals; Technetium Tc 99m Medronate

2003